Akari Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Akari Therapeutics PLC
AKTX Stock  USD 1.30  0.06  4.84%   
Akari Therapeutics financial statements provide useful quarterly and yearly information to potential Akari Therapeutics PLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Akari Therapeutics financial statements helps investors assess Akari Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Akari Therapeutics' valuation are summarized below:
Market Capitalization
30.3 M
Earnings Share
(2.58)
We have found one hundred twenty available fundamental signals for Akari Therapeutics PLC, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Akari Therapeutics PLC prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 14.5 M in 2024. Enterprise Value is likely to drop to about 10.9 M in 2024
Check Akari Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akari Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 6.4 M, Selling General Administrative of 7.6 M or Other Operating Expenses of 18 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Akari financial statements analysis is a perfect complement when working with Akari Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Akari Therapeutics Correlation against competitors.

Akari Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding4.7 M4.9 M4.3 M
Pretty Stable
Total Assets4.1 M4.4 M16.7 M
Very volatile
Other Current Liabilities5.7 M2.9 M5 M
Slightly volatile
Total Current Liabilities7.9 M4.6 M6.9 M
Pretty Stable
Accounts Payable2.1 M1.7 M1.8 M
Pretty Stable
Cash3.7 M3.8 M14.9 M
Very volatile
Cash And Short Term Investments3.7 M3.8 M15.6 M
Very volatile
Net Receivables2.7 M3.4 M3.4 M
Slightly volatile
Common Stock Total Equity420.3 K442.4 K8 M
Very volatile
Liabilities And Stockholders Equity4.1 M4.4 M16.7 M
Very volatile
Non Current Liabilities Total1.1 M1.1 M950.4 K
Slightly volatile
Other Stockholder Equity117.1 M174.8 M100.8 M
Slightly volatile
Total Liabilities8.1 M4.6 M7.1 M
Pretty Stable
Total Current Assets4.1 M4.3 M16.7 M
Very volatile
Common Stock1.3 M1.3 M8.1 M
Very volatile
Short and Long Term Debt Total456480180 K
Slightly volatile
Non Current Assets Total13.3 K14 K75.6 K
Very volatile
Property Plant And Equipment Gross207.7 K197.8 K80.3 K
Slightly volatile
Short Term Debt456480180 K
Slightly volatile
Short and Long Term Debt613.4 K480.2 K659.7 K
Slightly volatile
Intangible Assets13.3 K14 K19.6 K
Slightly volatile
Other Liabilities55.7 K55.2 K50 K
Slightly volatile
Other Current Assets954.4 K496 K679.9 K
Slightly volatile
Non Current Liabilities Other41.7 K43.2 K51.2 K
Slightly volatile
Capital Surpluse119.4 M127.1 M109.9 M
Slightly volatile
Capital Stock636.5 K670 K16.5 M
Slightly volatile

Akari Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative7.6 M11.4 M7 M
Slightly volatile
Other Operating Expenses18 M16.8 M16.5 M
Slightly volatile
Research Development10.9 M12.1 M10 M
Slightly volatile
Total Operating Expenses18.1 M16.8 M16.5 M
Slightly volatile
Interest Income39.3 K41.3 K3.4 M
Slightly volatile
Net Interest Income70.5 K41.3 K105.8 K
Slightly volatile
Reconciled Depreciation3.2 K3.3 K27.8 K
Slightly volatile
Selling And Marketing Expenses9.1 M10.2 M11.1 M
Slightly volatile

Akari Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow15.5 M13.2 M14.2 M
Pretty Stable
Total Cash From Financing Activities6.7 M7 M15.4 M
Pretty Stable
End Period Cash Flow3.7 M3.8 M14.9 M
Very volatile
Stock Based Compensation1.4 M1.1 M1.2 M
Pretty Stable
Depreciation3.8 K4 K12.8 K
Very volatile
Sale Purchase Of Stock16.9 M11.4 M13.9 M
Very volatile
Issuance Of Capital Stock17 M29 M8.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Invested Capital6.4 M5.9 M5.7 M
Slightly volatile
Average Payables2.4 M1.6 M2.5 M
Slightly volatile
Capex To Depreciation0.951.03.0136
Slightly volatile
Payables Turnover0.00230.00240.007
Very volatile
Cash Per Share0.750.78566.1546
Pretty Stable
Days Payables Outstanding160.1 K152.5 K114.1 K
Pretty Stable
Income Quality1.721.64190.9534
Slightly volatile
Tangible Asset Value5.9 M5.6 M5.2 M
Slightly volatile
Intangibles To Total Assets0.00340.00320.0013
Slightly volatile
Net Debt To EBITDA0.220.22880.7593
Pretty Stable
Current Ratio0.90.9472.4851
Very volatile
Graham Number1.391.467237.2959
Slightly volatile
Capex Per Share0.00320.00340.0173
Slightly volatile
Average Receivables6.6 K3.5 K4.9 K
Slightly volatile
Interest Debt Per Share0.850.893.679
Slightly volatile
Debt To Assets1.0E-41.0E-40.1604
Slightly volatile
Days Of Payables Outstanding160.1 K152.5 K114.1 K
Pretty Stable
Ebt Per Ebit0.740.59550.9095
Very volatile
Quick Ratio0.90.9472.5617
Very volatile
Net Income Per E B T0.890.450.8127
Slightly volatile
Cash Ratio0.80.83882.0222
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.80.90.9812
Slightly volatile
Debt Ratio1.0E-41.0E-40.1604
Slightly volatile

Akari Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap14.5 M15.3 M889.7 M
Slightly volatile
Enterprise Value10.9 M11.4 M468.3 M
Slightly volatile

Akari Fundamental Market Drivers

Cash And Short Term Investments3.8 M

Akari Upcoming Events

6th of May 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Akari Therapeutics Financial Statements

Akari Therapeutics investors use historical fundamental indicators, such as Akari Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Akari Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue(480.24)(504.25)
Cost Of Revenue4 K3.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Akari Stock Analysis

When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY